Dustin Wade Wooten, Ph.D.
This page shows the publications Dustin Wooten has written about Radiopharmaceuticals.
Pharmacokinetic Evaluation of the Tau PET Radiotracer 18F-T807 (18F-AV-1451) in Human Subjects. J Nucl Med. 2017 Mar; 58(3):484-491.
In vivo kinetics of [F-18]MEFWAY: a comparison with [C-11]WAY100635 and [F-18]MPPF in the nonhuman primate. Synapse. 2011 Jul; 65(7):592-600.
Evaluation of pharmacokinetic modeling strategies for in-vivo quantification of tau with the radiotracer [18F]MK6240 in human subjects. Eur J Nucl Med Mol Imaging. 2019 Sep; 46(10):2099-2111.
First-in-human evaluation of 18F-mefway, a PET radioligand specific to serotonin-1A receptors. J Nucl Med. 2014 Dec; 55(12):1973-9.
5-HT1A sex based differences in Bmax, in vivo KD, and BPND in the nonhuman primate. Neuroimage. 2013 Aug 15; 77:125-32.
Preclinical Validation of a Single-Scan Rest/Stress Imaging Technique for 13N-Ammonia Positron Emission Tomography Cardiac Perfusion Studies. Circ Cardiovasc Imaging. 2020 01; 13(1):e009407.
Comparative assessment of (18) F-Mefway as a serotonin 5-HT1A receptor PET imaging agent across species: Rodents, nonhuman primates, and humans. J Comp Neurol. 2016 May 01; 524(7):1457-71.
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.